|
|
|
|
|
American Vanguard Corp. (AVD)
Q2 2024 Earnings Call |
|
|
|
Corrected Transcript
08-Aug-2024 |
That said, the current management team and the board view our overall results as unacceptable. In our years
of experience with the company, we believe that the primary impediment of this business has not been in generating sales, but rather has been in managing our cost structure. Thus, it is incumbent upon us to take decisive action to reduce costs,
improve liquidity, and accelerate our business transformation.
Before turning to Mark on our multiple initiatives to effect this change, let me first
touch upon the subject of Dacthal. As you may have read in the press earlier this week, the EPA just issued an emergency suspension of that product which prevents its sale, distribution, and use. As you may recall, we voluntarily suspended sales of
Dacthal last April, and had submitted a much reduced label in an effort to meet the agencys concerns. In addition, at that time, we had removed Dacthal sales from our 2024 forecast assumptions. We are, of course, working in good faith with
both EPA and our stakeholders to ensure compliance with the suspension.
With that, let me turn to Mark Bassett on our multiple initiatives to improve
operating leverage and efficiency, both in the short term and permanently. Mark?
Mark R. Bassett
Board Member, American Vanguard Corp.
Thanks, Jim. Before
I get into the details, Id like to quickly introduce myself as per slide 11. First, Im a shareholder of American Vanguard. I invested in the company before I joined the board a little more than two years ago. Prior to that, I spent
almost six years as Chairman and CEO of Hemlock Semiconductor. During that time, we were able to significantly increase the valuation of the company by reducing the total costs by about 30%, while creating a substantial new revenue stream to drive
rapid growth. Prior to that, I ran several large global businesses at Dow. And early in my career, I worked in finance and technology.
I invested in
American Vanguard because I believed in the companys potential, and I still do. After joining the board, I spent 2.5 months inside the company last year developing the foundation of what became the transformation the company is helping us
implement. And Ive spent the last two months in the company focused on accelerating the transformation and helping improve liquidity in the second half. After my time here, theres no doubt in my mind that this is a solid company capable
of delivering a 15% EBITDA margin performance.
So with that as a preface, lets turn to slide 12, and then, get into some of the details of what
weve recently accomplished. First, we felt it was critical to get alignment throughout the company, and how we went to work and the priorities for the remainder of the year. Our mantra is teamwork, focus, performance, and urgency. This mantra
may sound simple, but its a key driver for success. I can tell you that there is a lot of excitement throughout the company and leadership is committed to realizing the companys full potential. For the remainder of the year, there are
four key priorities. One, cultivate our people. Two, improve liquidity. Three, accelerate the transformation. And four, operate the company across all functions excellently day in and day out.
To that end, weve created a one page blueprint with all key initiatives and key performance indicators with clear targets that we are tracking, acting
on, and communicating globally, so we know how were doing. This was recently rolled out to the entire company, and weve instituted a monthly run the business meeting to drive a more urgent and proactive response to changing conditions.
We believe this clarity and focus will allow us to better meet our commitments. The objective of these initiatives is to increase cash flow and create a consistently higher operating margin.
Turning to liquidity and inventory management on slide 13. First, wed like to discuss SIMPAS. The company has spent many years developing this
groundbreaking technology. At this point, we believe that weve proven the concept of a multi-product prescribed application. However, at this stage of commercialization, we believe that the
|
|
|
|
|
|
|
4 |
1-877-FACTSET www.callstreet.com |
|
Copyright © 2001-2024 FactSet CallStreet, LLC |